Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (10)
Total enrollment: 973 patients across 10 trials
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Related Jobs in Neurology
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Associate Director, Operational Procurement
Sales Support Representative (Temp-to-Hire)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.